Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals

ETNBVery BullishCorporate Developmentsnews

High materiality9/10

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Sep 18, 2025, 12:57 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The acquisition price is significantly higher than ETNB's current trading price, suggesting strong market confidence.

AI summary

What happened, with direct paths to the underlying reporting

Roche announces acquisition of 89bio for $2.4 billion. Acquisition price of $14.50 per share represents a 79% premium. 89bio's therapy pegozafermin targets liver and cardiometabolic diseases. Stockholders will receive contingent payments upon milestone achievements. ETNB's stock price up 85.15% following acquisition news.

Roche announces acquisition of 89bio for $2.4 billion.
Acquisition price of $14.50 per share represents a 79% premium.
89bio's therapy pegozafermin targets liver and cardiometabolic diseases.
Stockholders will receive contingent payments upon milestone achievements.
ETNB's stock price up 85.15% following acquisition news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push

Roche to Acquire 89bio in $3.5 Billion Deal for Liver Drug Development

Roche to acquire liver drug developer 89bio for up to $3.5 billion